Cargando…
Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients
Up to 10% of pediatric cancer patients harbor pathogenic germline variants in one or more cancer susceptibility genes. A recent study from the US reported pathogenic variants in 22 out of 60 analyzed autosomal dominant cancer susceptibility genes, implicating 8.5% of pediatric cancer patients. Here...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935871/ https://www.ncbi.nlm.nih.gov/pubmed/33674644 http://dx.doi.org/10.1038/s41598-021-84502-4 |
_version_ | 1783661085646127104 |
---|---|
author | von Stedingk, Kristoffer Stjernfelt, Karl-Johan Kvist, Anders Wahlström, Cecilia Kristoffersson, Ulf Stenmark-Askmalm, Marie Wiebe, Thomas Hjorth, Lars Koster, Jan Olsson, Håkan Øra, Ingrid |
author_facet | von Stedingk, Kristoffer Stjernfelt, Karl-Johan Kvist, Anders Wahlström, Cecilia Kristoffersson, Ulf Stenmark-Askmalm, Marie Wiebe, Thomas Hjorth, Lars Koster, Jan Olsson, Håkan Øra, Ingrid |
author_sort | von Stedingk, Kristoffer |
collection | PubMed |
description | Up to 10% of pediatric cancer patients harbor pathogenic germline variants in one or more cancer susceptibility genes. A recent study from the US reported pathogenic variants in 22 out of 60 analyzed autosomal dominant cancer susceptibility genes, implicating 8.5% of pediatric cancer patients. Here we aimed to assess the prevalence of germline pathogenic variants in these 22 genes in a population-based Swedish cohort and to compare the results to those described in other populations. We found pathogenic variants in 10 of the 22 genes covering 3.8% of these patients. The prevalence of TP53 mutations was significantly lower than described in previous studies, which can largely be attributed to differences in tumor diagnosis distributions across the three cohorts. Matched family history for relatives allowed assessment of familial cancer incidence, however, no significant difference in cancer incidence was found in families of children carrying pathogenic variants compared to those who did not. |
format | Online Article Text |
id | pubmed-7935871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79358712021-03-08 Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients von Stedingk, Kristoffer Stjernfelt, Karl-Johan Kvist, Anders Wahlström, Cecilia Kristoffersson, Ulf Stenmark-Askmalm, Marie Wiebe, Thomas Hjorth, Lars Koster, Jan Olsson, Håkan Øra, Ingrid Sci Rep Article Up to 10% of pediatric cancer patients harbor pathogenic germline variants in one or more cancer susceptibility genes. A recent study from the US reported pathogenic variants in 22 out of 60 analyzed autosomal dominant cancer susceptibility genes, implicating 8.5% of pediatric cancer patients. Here we aimed to assess the prevalence of germline pathogenic variants in these 22 genes in a population-based Swedish cohort and to compare the results to those described in other populations. We found pathogenic variants in 10 of the 22 genes covering 3.8% of these patients. The prevalence of TP53 mutations was significantly lower than described in previous studies, which can largely be attributed to differences in tumor diagnosis distributions across the three cohorts. Matched family history for relatives allowed assessment of familial cancer incidence, however, no significant difference in cancer incidence was found in families of children carrying pathogenic variants compared to those who did not. Nature Publishing Group UK 2021-03-05 /pmc/articles/PMC7935871/ /pubmed/33674644 http://dx.doi.org/10.1038/s41598-021-84502-4 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article von Stedingk, Kristoffer Stjernfelt, Karl-Johan Kvist, Anders Wahlström, Cecilia Kristoffersson, Ulf Stenmark-Askmalm, Marie Wiebe, Thomas Hjorth, Lars Koster, Jan Olsson, Håkan Øra, Ingrid Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients |
title | Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients |
title_full | Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients |
title_fullStr | Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients |
title_full_unstemmed | Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients |
title_short | Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients |
title_sort | prevalence of germline pathogenic variants in 22 cancer susceptibility genes in swedish pediatric cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935871/ https://www.ncbi.nlm.nih.gov/pubmed/33674644 http://dx.doi.org/10.1038/s41598-021-84502-4 |
work_keys_str_mv | AT vonstedingkkristoffer prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT stjernfeltkarljohan prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT kvistanders prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT wahlstromcecilia prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT kristofferssonulf prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT stenmarkaskmalmmarie prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT wiebethomas prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT hjorthlars prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT kosterjan prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT olssonhakan prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients AT øraingrid prevalenceofgermlinepathogenicvariantsin22cancersusceptibilitygenesinswedishpediatriccancerpatients |